Novartis completes $12 billion acquisition of Avidity Biosciences

The deal was executed via a merger of Novartis’ wholly owned subsidiary, Ajax Acquisition Sub, Inc., into Avidity

Glenmark Pharmaceuticals USA to launch sodium phosphates injection

The product addresses a market with approximately $66.8 million in annual sales as of December 2025.

Pfizer and Astellas report groundbreaking results in muscle-invasive bladder cancer trial

Merck’s KEYTRUDA shows significant survival boost in platinum-resistant ovarian cancer

KEYTRUDA had previously met its primary endpoint of progression-free survival in all patients

Eli Lilly and Incyte score key win for teens with severe alopecia areata in Europe

AA, a chronic immune disease, can cause extensive and unpredictable hair loss

Combination therapy cuts death Risk in advanced prostate cancer: PEACE-3 trial

PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer

Novartis’ remibrutinib bags positive CHMP opinion for chronic urticaria

The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines

Star Health & Allied Insurance rolls out 32 free primary care clinics across 9 states

The initiative, funded entirely under the company’s CSR programme, is expected to reach over a million lives

Pfizer bags rull FDA nod for BRAFTOVI combination in aggressive colorectal cancer

BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results

Novo Nordisk & Vivtex team up to revolutionize oral hiologics

Under the deal, Vivtex will license select oral drug-delivery technologies to Novo Nordisk